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CObjectives: Major depressive disorder (MDD) is a major public health
concern associated with a high burden to society, the health-care
system, and patients and an estimated cost of €3.5 billion in Sweden.
he objective of this study was to assess the cost-effectiveness of
scitalopram versus generic venlafaxine extended-release (XR) in
DD, accounting for the full clinical profile of each, adopting the
wedish societal perspective, and identifying major cost drivers.
ethods: Cost-effectiveness of escitalopram versus venlafaxine XR
as analyzed over a 6-month time frame, on the basis of a decision
ree, for patients with MDD seeking primary care treatment in Swe-
en. Effectiveness outcomes for the model were quality-adjusted
ife-years and probability of sustained remission after acute treat-
ent (first 8 weeks) and sustained for 6 months. Cost outcomes
ncluded direct treatment costs and indirect costs associated with
ick leave. Results: Compared with generic venlafaxine XR, escitalo-
ramwas less costly andmore effective in terms of quality-adjusted life-
ears (expected gain 0.00865) and expected 6-month sustained remission O
37–4
al So
oi:10.1016/j.jval.2011.09.011robability (incremental gain 0.0374). Thebetter tolerability profile of esci-
alopram contributed to higher expected quality-adjusted life-years and
ower health-care resource utilization in terms of pharmacological treat-
ent of adverse events (though only a minor component of treatment
osts). Expected per-patient saving was €169.15 for escitalopram versus
enlafaxine. Cost from sick leave constituted about 85% of total costs.
onclusions: Escitalopramwas estimated asmore effective and cost
aving than generic venlafaxine XR in first-line MDD treatment in
weden, driven by the effectiveness and tolerability advantages of
scitalopram. The study findings are robust and in line with similar
harmacoeconomic analyses.
eywords: cost-effectiveness, first-line therapy, major depressive dis-
rder (MDD), remission, selective norepinephrine reuptake inhibitor
SNRI), selective serotonin reuptake inhibitor (SSRI).
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background
Globally, major depressive disorder (MDD) is a major public
health concern associated with a high burden to society, health-
care system, and patients. In Sweden, the estimated cost of
depression doubled between 1997 and 2005, from €1.7 to €3.5
billion [1]. This cost increase was primarily driven by an in-
crease in indirect costs associated with sick leave and early
retirement, over the past decade, whereas direct costs re-
mained relatively stable over time [1].
The pharmacological treatment options in MDD include selec-
tive serotonin reuptake inhibitors (SSRIs) and serotonin norepi-
nephrine reuptake inhibitors. In a meta-analysis, venlafaxine, a
serotonin norepinephrine reuptake inhibitor, has been shown to
be more effective than traditional SSRIs [2]. Escitalopram, the S
enantiomer of citalopram, is the most selective SSRI available [3];
in recent clinical studies, escitalopramwas shown to be at least as
* Address correspondence to: Natalya Danchenko, Lundbeck SAS,
rance.
E-mail: NADO@Lundbeck.com
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.efficacious as venlafaxine extended-release (XR), but with a better
tolerability profile [4-7].
Clinical efficacy and tolerability are the first considerations
when choosing an antidepressant drug (AD), but consideration
of cost is also becoming increasingly important. Several cost-
effectiveness (CE) studies of escitalopram versus venlafaxine
XR have shown that the clinical advantages of escitalopram
translate into benefits in real-life effectiveness: reduction in
sick leave and health-care resource utilization (outpatient and
inpatient care, pharmacological treatment, etc.) and associated
costs [8-12]. These CE studies, however, tended to focus on ef-
ficacy without considering the impact of tolerability on quality
of life. In addition, in countries such as Sweden, where a generic
formulation of venlafaxine XR has recently become available,
the CE of escitalopram versus venlafaxine XR needs to be re-
evaluated.
In Sweden, with a single-payer health-care system and a
strong health technology assessment outlook, adequate up-to-
5 Quai du Président Roosevelt, 92445 Issy-les-Moulineaux Cedex,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
232 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 3 1 – 2 3 9date evidence of CE is essential for decision making. The objec-
tive of the present analysis was to assess the CE of escitalopram
versus generic venlafaxine XR in MDD, accounting for the full
clinical profile (efficacy and tolerability) of the two ADs, adopt-
ing the societal perspective in Sweden, and identifying the ma-
jor cost drivers associated with the management of depression.
Methods
A CE analysis of escitalopram versus venlafaxine XR was con-
ducted over a 6-month time frame from the societal perspective,
based on a decision tree. In this model, escitalopram was com-
pared with generic venlafaxine XR, an AD of the serotonin norepi-
nephrine reuptake inhibitor class. BothADs are reimbursed for the
treatment of depression in Sweden [13], and the market share of
venlafaxine is expected to increase since it became generic in Swe-
den in 2009. The target population consisted of adult patients
(aged 18–65 years) with moderate to severe MDD seeking treat-
ment in a primary care setting in Sweden, consistently with un-
derlying clinical data. The effectiveness outcomes for the model
were quality-adjusted life-years (QALYs) and the probability of
sustained remission, defined as a remission (Montgomery Åsberg
Depression Rating Scale total score 12) achieved during acute
treatment (first 8 weeks of treatment) and sustained until the end
of the 6-month time frame. Cost outcomes included direct treat-
ment costs (ambulatory care, hospitalizations, pharmacological
therapy [AD use accounting for titration; treatment of adverse
events, AEs]) and indirect costs associated with sick leave.
Model structure
A decision analytic model was created by using a previously pub-
lished model of escitalopram versus sertraline [14], modified to
reflect clinical practice patterns associated with the use of escita-
lopramand venlafaxine in the treatment ofMDD in Sweden, based
on newly available data, including long-term relapse data (i.e.,
relapse in patientswhohad achieved remission). The decision tree
is presented in Figure 1. The 6-month time frame for the model,
common for economic evaluations of ADs [15,16], was chosen to
Fig. 1 – Cost-effectiveness model of escitalopram or venlafax
1) The venlafaxine arm is a clone of the escitalopram arm (im
patients who achieved remission at week 8 since treatment
were expected to continue on the same medication for anot
who achieved remission at week 8 since treatment initiation
Patients who did not achieve remission during the first 8 wk
Patients who did not achieve remission during the first 8 wk
was developed by using Data 4.0 software (TreeAge Softwar
escitalopram; MDD, major depressive disorder.capture the largest proportion of clinical events within a given
depressive episode (remission, AEs, relapses) but without being
too long that extrapolations beyond the available clinical and real-
life data would jeopardize the accuracy of the model. This time
frame also limited the number of assumptions and the number of
pathways (the overall structure)within themodel. To populate the
model, clinical trial data over 8weekswere used, supplemented as
much as possible by data from the country-specific real-life study
HEADIS (a naturalistic longitudinal Swedish survey) [14]. The ini-
tial 2-month acute treatment was assumed to start with either
10 mg escitalopram or 75 mg venlafaxine XR, with a possible dose
adjustment during the second month (to escitalopram 20 mg/d or
venlafaxine 150 mg/d, respectively), in line with the dose recom-
mendations for both products, according to the Summary of Product
Characteristics. During this acute treatment period, patients could
achieve remission of symptoms (Montgomery Åsberg Depression
Rating Scale score 12). Patients who achieved remission during
this period were assumed to continue medication for a 4-month
maintenance period. During this maintenance treatment, patients
could relapse or remain in remission (sustained remission). Patients
who did not achieve remission during the 8 weeks of initial therapy
either switched to anotherADor stopped the treatment prematurely
(based on real-life practice assessed as detailed below).
The results of the analysiswere estimated on the basis of utilities
and costs associated with different health states (as detailed below).
The model was run as a Monte Carlo simulation comprising 10,000
iterations, resulting in 95% credibility intervals of point estimates of
incremental costs and effectiveness (QALYs and probability of sus-
tained remission) for escitalopram versus venlafaxine.
The model was developed by using Data 4.0 software (TreeAge
Software, Inc., Williamstown, MA).
Data sources and model assumptions
Clinical inputs
The clinical inputs for remission, AEs, and relapse probabilities for
each treatment arm are shown in Table 1. The 8-week remission
probabilities were derived from a pooled analysis of two random-
ized controlled trials (RCTs) of venlafaxine and escitalopram [7].
extended-release for major depressive disorder in Sweden:
ing the same structure). 2) Sustained remission at 6 mo:
ation and remaining in remission by week 24. Patients
mo (maintenance therapy). 3) Relapse at 6 mo: Patients
subsequently relapsed. 4) Premature stop at 8 wk:
herapy and stopped medication. 5) Switch at 8 wk:
herapy and switched to another medication. 6) The model
c., Williamstown, MA). AD, antidepressant drug; Esc,ine
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233V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 3 1 – 2 3 9The probability of sustained remission over the total 6-month
time frame was estimated from the naturalistic longitudinal
Swedish survey HEADIS [14], capturing data for patients with de-
ression in 56 primary care centers in Swedenwhowere initiating
new AD therapy or changing ongoing therapy. The probabilities
f sustained remission were based on physician judgment as doc-
mented in the HEADIS andwere not treatment specific due to the
mall number of patients reporting sustained remission. The
-month relapse probability for patients who achieved remission
ver the initial 8 weeks of treatment was estimated as comple-
entary to the probability of sustained remission. The relapse
robabilities were assumed to be the same irrespective of the
reatment, on the basis of other placebo-controlled studies show-
ng that the probabilities of relapse are relatively similar [17-20].
Because of data limitations, the model accounted for occur-
ence of AEs during the first 2months of treatment only, using the
ata on treatment-specific probabilities of AEs from the same
ooled analysis [7]. Only those AEs that occurred in at least 7% of
he patients in any treatment arm in the pooled analysis were
ncluded in the model (the 7% cutoff allowed selection of relevant
nd meaningful AEs).
Treatment patterns
Asmentioned above, thismodel assumed initiation of an AD ther-
apy with the usual initial dosing of 10 mg escitalopram and 75 mg
venlafaxine as recommended in the Summary of Product Character-
istics. A possible need for a dose adjustment during the acute treat-
ment was reflected in the model as a treatment-specific probabil-
ity of titration (to 20 mg/d escitalopram or 150 mg/d venlafaxine,
respectively) in the secondmonth of treatment, with probabilities
based on the HEADIS data (Table 1) [14].
The probability of switch in case of nonresponse to the initial
8-week treatment was estimated on the basis of HEADIS data as
nontreatment specific due to sample size constraints; the proba-
bility of stopping treatment because of nonresponse to the acute
8-week therapy was estimated as complementary to the switch
probability (Table 1).
Utilities
Utilities associated with remission, treatment stop, and switch
Table 1 – Clinical probabilities (8 wk).
Utility
decrement,
mean (SE)
Valu
Esc
Remission probability — 62.1%
Stop probability — 52.4%
Switch probability — 47.6%
Relapse probability — 11.7%
Adverse events
Diarrhea 0.044 0.006 7%
Dry mouth 0.085 0.011 7%
Ejaculation disorder 0.049 0.006 0.8%
Fatigue 0.085 0.011 4.1%
Headache 0.115 0.015 13.5%
Impotence 0.049 0.006 2%
Insomnia 0.129 0.016 8.2%
Nausea 0.065 0.008 12.7%
Somnolence 0.085 0.011 7.4%
Sweating 0.085 0.011 5.7%
Titration probability — 21.84%
Esc, escitalopram; SE, standard error; Ven, venlafaxine; XR, extendedwere taken from the HEADIS data, assessed by using the EuroQoLfive-dimensional scale (Table 2). Over the 6-month time frame,
utilities specific to each treatment outcome were calculated as
follows. Remitted patients onmaintenance therapywere assumed
to have the average of baseline and remission utility over the first
8 weeks and the utility associated with remission for the remain-
ing 16 weeks. Nonremitting patients switching after the first 8
weeks were assumed to have the average of baseline and utility
related to switch over the 8 first weeks of medication and the
utility associated with switch for the remaining 16 weeks (similar
calculation applied for nonremitting patients stopping treatment,
but applying utility related to treatment stop).
Patients with AEs were assumed to have a decrement in utility
associated with the AEs over the first 8 weeks; these AE-related
utility decrementswere derived fromapublished economicmodel
in depression [16], originally based on the 2000 Medical Expendi-
ture Panel Survey [21].
Resource utilization
Six-month resource use associated with different health states/
treatment outcomes (remission vs. switch or stop of treatment in
case of nonremission) was estimated from HEADIS [14] (Table 2),
including hospitalization (number of bed days) and ambulatory
care (general practitioner [GP], specialist, nurse, psychologist/
therapeutic, counselor, and emergency visits). It was assumed
that patients titrated to a higher dose needed an additional GP
visit, and the number of such additional visits per patient was
assumed to be equal to the estimated average number of titrations
per patient in patients who had up-titration (in the period before a
switch in medication in the HEADIS study).
Medication
In the presentmodel, estimation of pharmacologicalmedication use
was based on prescriptions for ADs and AE-related medication. AD
use accounted for a switch option after 8 weeks of initial treatment;
for patients who switch, the AD cost over the last 4-month period
wasbasedon theaverageof the fourmost commonlyprescribedADs
based on IMS data to April 2009 (IMS Midas, April 2009).
Medications to treat AEs were identified by two Swedish med-
ical experts. The cost of treatment for anAEwas assumed to be the
price of the lowest package ofmedication andwas taken from The
Distribution Reference
n Esc Ven Esc and Ven
% Beta (243, 151) Beta (240, 139) [7]
Beta (82, 43) [16]
Beta (82, 39) [16]
Beta (175, 54) [16]
[7]
Beta (244, 17) Beta (243, 17)
% Beta (244, 17) Beta (243, 25)
% Beta (244, 2) Beta (243,12)
Beta (244, 10) Beta (243, 17)
Beta (244, 33) Beta (243, 27)
% Beta (244, 5) Beta (243, 2)
% Beta (244, 20) Beta (243, 23)
% Beta (244, 31) Beta (243, 62)
% Beta (244, 18) Beta (243, 21)
% Beta (244, 14) Beta (243, 29)
%
8% Beta (87, 19) Beta (34, 14) [16]
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234 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 3 1 – 2 3 9medelsförmånsverket) database. If the two experts reported dif-
ferentmedications for a particular AE, the average cost for the two
different drugs was considered.
Productivity loss inputs
Productivity losses were estimated from the HEADIS study, based
on reported sick days (related to depression or not) for patients
achieving remission and for those who stopped or switched med-
ication because of nonresponse to an initial treatment (Table 2).
The number of days reported in the study was based on a working
week excluding weekends.
Unit costs
Medical resource use and sick leave were valued by unit costs
obtained from the Regional Joint Committee of the Southern Swe-
denHealth Care Region price list for 2009 and the Confederation of
Swedish Enterprise (2007), respectively. Visits to doctors other
than those specified (i.e., neurologist, cardiologist) were not very
common and were assigned the unit cost of a neurologist (the
most common of these other doctors). In addition, the cost for a
psychologist visit was assigned to visits with other related health-
care professionals (e.g., counselors). Unit costs from 2007 were
inflated to 2009 costs by using published inflation rates (http://
www.ekonomifakta.se/en). The unit costs for escitalopram and
venlafaxine XR were taken from The Dental and Pharmaceutical
Benefits Agency from April 2009 (www.tlv.se) (Table 3). Unit costs
or a weekly wage based on a 7-day week were adjusted (*5/7) to
lign with the working days estimates from HEADIS. The CE of
scitalopram versus venlafaxine XR was assessed by using two
cenarios: the current price for generic venlafaxine (“base sce-
ario”) and a more conservative estimate assuming a price for
eneric venlafaxine XR as 5% of branded venlafaxine XR (“conser-
ative scenario”).
The model inputs and outputs were defined in SEK, but the
orresponding values in € are reported in the present article to
acilitate interpretation beyond the Swedish health-care system.
he exchange rate used was that for December 1, 2009 (1 SEK 
.0960 €); costs were calculated to two decimal places (http://
ww.ecb.europa.eu/stats/eurofxref/eurofxref-hist-90d.xml). No
iscounting was applied over the 6-month time frame of the
Table 2 – Utility and resource utilization per patient for inp
Remission (n 
Inpatient care (bed-days)
Psychiatric inpatient stay 0.17 (1.81)
Outpatient care (visits)
GP 3.15 (1.80)
GP phone follow-up 1.10 (1.57)
Psychiatrist 0.05 (0.37)
A&E 0.18 (0.66)
Other doctors (e.g., neurologist) 0.49 (1.84)
Nurse 0.19 (1.45)
Psychologist 0.23 (1.34)
Counselor 0.09 (0.82)
Other health professional 0.57 (2.79)
Production loss (d)
Sick leave 38.45 (59.68)
Utility, mean (SE) 0.800 (0.017)
Source: Sullivan et al. [16].
Data distribution is Gamma (Param1; Param2) where Param1 mean
A&E, acute and emergency; GP, general practitioner; SE, standard errodel.Sensitivity analyses
The base-casemodel was assessed by usingMonte Carlo simulation
to account for multivariate uncertainty inherent to input parame-
ters, using beta distributions (the most appropriate distribution to
model an event probability) for probabilities of remission, relapse,
AEs, change in therapeutic management and titration, gamma dis-
tribution (the most appropriate distribution to model resource use)
for resource use, and normal distribution for utility values. In addi-
tion, one-way sensitivity analyseswere performed for keymodel pa-
rameters— probability of remission for escitalopram, the number of
sick-leave days (key cost driver), number of GP visits for each remis-
sion, switchandstop status (key componentof outpatient costs), and
incidence of nausea with escitalopram (side effect with biggest im-
pact on costs and utility). Finally, a willingness-to-pay analysis was
performed by using a threshold value of €22,080 and €28,800. These
alues correspond to £20,000 to £30,000 per QALY gained used by the
K National Institute for Health and Clinical Excellence as an upper
imit for defining a technology as an effective use of health service
esources within a nationally based health-care system (www.ni-
e.org.uk).
Results
Base scenario analysis
From the societal perspective, in the base-case scenario analy-
sis, escitalopram dominated venlafaxine XR. Patients treated
with escitalopram had a mean expected number of QALY of
0.3151 compared with a mean expected QALY of 0.3065 for ven-
lafaxine-treated patients (yielding an expected gain of 0.00865
with escitalopram vs. venlafaxine) (Table 4). The expected sus-
tained remission probabilities were 0.549 and 0.511, respec-
tively, yielding an incremental gain of 0.0374 with escitalopram
versus venlafaxine.
The estimated average 6-month overall cost was €7377.89 per
atient for escitalopram and €7547.04 per patient for venlafaxine.
onsequently, the expected per patient saving was €169.15 per
patient for escitalopram versus venlafaxine.
Cost from sick leave constituted the major component of the
overall cost, at about 85% in both treatment arms. For direct treat-
t care, outpatient care, and productivity loss over 6 mo.
Mean (SD)
Switch (n  43) Stop (n  39)
0.78 (5.11) 0.54 (2.94)
4.39 (2.16) 4.80 (5.51)
1.61 (1.35) 2.29 (3.83)
0.34 (0.86) 0.24 (0.92)
0.17 (0.44) 0.37 (0.96)
0.13 (0.51) 2.26 (7.86)
0.43 (1.95) 0.46 (1.33)
0.83 (2.57) 0.42 (1.48)
0.06 (0.38) 0.41 (2.59)
0.43 (1.80) 1.95 (8.43)
81.32 (78.42) 48.57 (68.21)
0.480 (0.044) 0.520 (0.042)
2 and Param2 mean/SD.2atien
171)
2/SDment costs, the highest proportion was due to GP visits.
w, Apri
235V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 3 1 – 2 3 9The robustness of the observation that escitalopram was less
costly and more effective in terms of QALYs gained (utilities) and
the expected probability of sustained remission was tested in a
Monte Carlo simulation of 10,000 iterations (i.e., patients), re-
sulting in a 62.2% probability that escitalopram was the domi-
nant therapy (Fig. 2). The CE acceptability curve from the Monte
Carlo simulation is presented in Figure 3, showing that with a
illingness to pay of €22,080 and €33,600 per QALY gained, escita-
lopram had 78.4% and 82.3% probability, respectively, of being
cost-effective compared with venlafaxine (Fig. 3).
One-way sensitivity analyses
Sensitivity analyses found that the decision analytic model was
most sensitive to the escitalopram remission probability. In the
base case, the escitalopram remission probability (8 weeks) was
0.621, producing a difference of 0.00865 and –€169.15 per patient in
terms of expected QALYs and expected cost, respectively, com-
paredwith venlafaxine.When the remission probability with esci-
talopramwas decreased to the lower limit of the confidence inter-
val (0.559), the incremental QALY decreased to 0.0009 and the
incremental overall societal cost with escitalopram versus venla-
Table 3 – Unit costs for resource use (€ 2009) and antidepre
Resource use category
Outpatient GP
Follo
Psych
Neur
Acut
Psych
Nurs
Inpatient Psych
Sick leave Sick
AD cost Escit
Escit
Base analysis (generic venlafaxine price) Venla
Venla
Conservative analysis (5% of branded venlafaxine price) Venla
Venla
Other AD costs Four
Medications to treat AEs
Diarrhea Imod
Dizziness NA
Dry mouth Saliv
Xerod
Ejaculation disorder NA
Fatigue NA
Headache Alved
Pano
Impotence Viagr
Increased sweating NA
Insomnia Zopik
Nausea Lergi
Posta
Prim
Somnolence NA
Weight decrease NA
Unit costs associated with other doctors were based on neurologis
counselor were based on the unit cost for a psychologist.
AD, antidepressant drug; AE, adverse event; GP, general practitioner;
* The Regional Joint Committee of the Southern Sweden Health Care
http://www.ekonomifakta.se/en. The model inputs and outputs we
(1 SEK  €0.0960); costs were calculated to two decimal places (http
† Confederation of Swedish Enterprise (www.svensktnaringsliv.se), 2
‡ The Dental and Pharmaceutical Benefits Agency (TLV, www.tlv.se)faxine increased to €96.48 per patient (Table 5).Because costs associated with sick leave were a major contrib-
utor to overall costs, the model was tested on robustness to the
number of sick-leave days. Varying this parameter (sick leave as-
sociated with remission, switch, and stop of treatment) over the
95% confidence limits had an impact on the expected per-patient
cost, but escitalopram remained a cost-saving therapy compared
with venlafaxine (Table 5).
Likewise, the conclusions on cost savings associated with esci-
talopram versus venlafaxine XR did not change by varying the
number of GP visits, the major driver of direct costs.
Finally, the sensitivity analysis was performed on the inci-
dence of nausea, the AE with the greatest impact on QALYs. Vari-
ation of this input parameter around the confidence limits re-
sulted in corresponding changes in QALYs without changing the
conclusions of the base-case analysis regarding the greater effec-
tiveness of escitalopram versus venlafaxine.
Conservative scenario analysis
In the conservative analysis (assuming that generic venlafaxine XR
will cost 5% of branded venlafaxine), escitalopram remained domi-
nant to venlafaxine XR, with an incremental effectiveness similar to
t medication costs (€ 2009).
Resource use item Unit cost Source
85.82 *
call (GP) 35.04 *
t 280.99 *
t 184.99 *
emergency 229.44 *
ist and other related professionals 150.43 *
35.04 *
t (bed-day) 456.38 *
(daily wage) 180 †
m (10 mg/d) 0.93 ‡
m (20 mg/d) 1.62 ‡
e XR (75 mg/d) 0.70 ‡
e XR (150 mg/d) 0.97 ‡
e XR (75 mg/d) 0.01 ‡
e XR (150 mg/d) 0.10 ‡
commonly prescribed ADs 0.30 IMS
‡
2 mg) 5.66
0
g)
0.25 mg)
5.06
0
0
00 mg)
0 mg)
5.57
mg) 34.56
0
7.5 mg) 39.36
5 mg)
5 mg)
(10 mg)
8.50
0
0
t cost. Also, unit costs for psychotherapist, cognitive therapy, and
not applicable; XR, extended release.
n price list for 2007 inflated to 2009 cost by using inflation indices of
fined in SEK. The exchange rate used was that for December 1, 2009
w.ecb.europa.eu/stats/eurofxref/eurofxref-hist-90d.xml).
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236 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 3 1 – 2 3 9societal perspective. When considering a willingness to pay of
€22,080 and €33,600 per QALY gained, in the conservative analysis
scitalopram still had 67.8% and 74.4% probability, respectively, of
eing cost-effective compared with venlafaxine XR from a societal
erspective. In the same conservative scenario, accounting for direct
osts only, escitalopram was associated with an estimated incre-
ental per-patient cost of €76.51 (and still the same gain in QALYs).
Discussion
This was the first CE analysis comparing escitalopram with the
generic venlafaxine. The results showed that compared with ge-
neric venlafaxine XR, escitalopramwas less costly andmore effec-
tive in terms of QALYs and an expected 6-month sustained remis-
sion probability. The better tolerability profile of escitalopram
compared with that of venlafaxine contributed to higher expected
QALYs and lower health-care resource utilization in terms of phar-
Table 4 – Results of the cost-effectiveness analysis: effectiv
(total and by components), € 2009.
Escitalopram
Mean
(95% CI)
% of total
costs
Effectiveness
QALYs 0.3151 (0.2993–0.3302) —
Sustained remission
(over 6 mo)
0.549 (0.494–0.601) —
Costs
Inpatient costs 167.42 (0–1698.53) 2.27
Outpatient costs 818.11 (281.66–2385.22) 11.09
Antidepressant
treatment costs
147.74 (138.72–157.34) 2.00
Costs attributable to AEs 3.65 (2.88–4.51) 0.05
Direct costs 1136.93 (446.11 to 3471.55) 15.41
Indirect costs 6240.96 (640.90 to 20,341.15) 84.59
Total costs 7377.89 (1518.24 to 21,629.86) 100
AEs, adverse events; CI, confidence interval; QALYs, quality-adjusted
Fig. 2 – The cost-effectiveness of escitalopram compared wit
incremental total cost, base analysis. QALYs, quality-adjusted lifmacological treatment of AEs (though only a minor component of
treatment costs).
The results from two randomized, multicenter, double-blind,
8-week studies that compared the efficacy and tolerability of esci-
talopram and venlafaxine XR [4,5] were used as data sources both
in the pooled analysis used as the basis for clinical inputs in this
economic analysis [7] and in the more recently published Co-
chrane review of escitalopram [22]. Although the escitalopramCo-
chrane review was unpublished at the time this analysis was
carried out, the outcomes from these two different comparisons of
escitalopram and venlafaxine XR are consistent with regard to
both efficacy and tolerability. Specifically, the review found no
evidence that escitalopramwasmore or less efficacious than ven-
lafaxine in all parameters reported (i.e., proportion of patients
who responded to treatment after 6–12 weeks or early response
[1–4 weeks], proportion of patients who achieved remission after
6–12 weeks, and mean change from baseline in measures of de-
s outcomes (QALYs; sustained remission) and costs
Venlafaxine XR Incremental
(95% CI)
Mean
(95% CI)
% of total
costs
65 (0.2903–0.3217) — 0.00865 (0.00244 to 0.01989)
11 (0.456–0.565) — 0.0374 (0,0396 to 0,0396)
.79 (0–1801.25) 2.36 10.27 (147.46 to 17.95)
.54 (305.95–2473.73) 11.40 42.53 (220.42 to 63.55)
.02 (103.49–116.74) 1.46 37.73 (26.69–48.96)
.32 (3.65–5.09) 0.06 0.77 (1.82 to 0.38)
.77 (435.17 to 3577.54) 15.27 15.84 (290.30 to 127.10)
.27 (675.26 to 20,181.41) 84.73 153.31 (1577.76 to 1088.64)
.04 (1571.04 to 21,371.23) 100 169.15 (1632.19 to 1070.11)
ears.
nlafaxine extended-release: incremental QALYs versusenes
0.30
0.5
177
860
110
4
1152
6394
7547h ve
e-years.
237V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 3 1 – 2 3 9pressive symptoms) and that there was no evidence that escitalo-
pram was associated with a lower rate of AEs than venlafaxine,
besides nausea and increased sweating [22].
The economic model results were shown to be most sensitive
to changes in escitalopram remission. In addition to one-way sen-
sitivity analyses of these inputs, Monte Carlo analyses that varied
the probability of remission for both treatments simultaneously
(alongwith a number of other parameters) were carried out. These
analyses also showed a high probability that escitalopram was a
cost-effective treatment option.
Cost from sick leave constituted about 85% of the total costs.
Therefore, the benefit of escitalopram in terms of sick-leave re-
duction was a major driver of the overall cost savings compared
with venlafaxine XR. The cost of outpatient care/physician visits
accounted for a major proportion of the direct costs; hence, de-
creasing the number of physician visits because of improved treat-
ment effectiveness and reduced frequency of AEs (requiring addi-
tional health-care resource consumption) resulted in savings in
direct costs, in addition to improved productivity and reduction in
associated indirect costs.
Themodel was robust to variation of the key input parameters.
In the current analysis, AD treatment cost constitutes only aminor
portion of the direct treatment costs (and only 1.46%–2.00% of the
total costs); evenwith the conservative assumption of venlafaxine
unit cost amounting to 5% of the branded price, escitalopram re-
mained a dominant treatment option comparedwith venlafaxine.
These results are in line with findings from other pharmaco-
economic studies comparing escitalopramwith venlafaxine XR. In
themodel by Sullivan et al. [16], also accounting for both effective-
ness and tolerability advantages of escitalopram versus venlafax-
ine XR, escitalopramwas associated with an incremental QALY of
0.005 per patient and a cost saving equivalent to €502.50 compared
with venlafaxine XR for initial treatment over 6 months. The ex-
change rate used was that for December 1, 2009 (€1  US$0.66);
costs were calculated to two decimal places (http://www.ecb
.europa.eu/stats/eurofxref/eurofxref-hist-90d.xml) [16]. Other stud-
ies driven by effectiveness but not accounting for tolerability im-
Fig. 3 – Cost-effectiveness acceptability curve for base scena
life-year.pact on health-related quality of life also reported economicadvantages of escitalopram versus venlafaxine. In the economic
model by Kulp et al. [12], savings per treatment responder with
escitalopram versus venlafaxine amounted to €43 under GP and
€58 under specialist treatment (equivalent to 34% and 42%), re-
spectively. In other decision-analytic modeling studies using indi-
rect comparative clinical trial data, escitalopram was cost saving
versus SSRIs and venlafaxine [8-10,23-25]. In the prospective anal-
ysis by Fernandez et al. [11] comparing escitalopramand venlafax-
ine XR based on direct clinical comparative data alongside an in-
ternational clinical trial, after adjustment for key baseline factors,
escitalopram was associated with 40% lower direct health-care
costs than venlafaxine XR (95% confidence interval 10–81; P 
0.007). In that study, indirect costs due to sick leave accounted
for at least 80% of the total cost in both treatment arms. It
should be noted, however, that previous analyses did not con-
sider generic venlafaxine.
Limitations
As with any pharmacoeconomic modeling analysis, there are lim-
itations to thismodel. For instance, biasmay be present because of
compiling data from different sources; specifically, the remission
and relapse data are derived from RCTs and the HEADIS data set,
respectively. The advantage of the observational HEADIS data,
however, is the specificity to Sweden and reflection of the local
practice patterns, allowing the assessment of real-life effective-
ness and economic implications of efficacy and tolerability bene-
fits of the drug beyond the conditions of RCTs. In addition, the
patient populationwas comparable between the two data sources:
the RCTs focused onpatientswith an episode ofMDD,while 75%of
the patients in the HEADIS data set were defined as moderately or
severely ill.
The use of a 6-month time frame may be a limitation of this
model, given the chronic nature of MDD and the likelihood of the
need for long-term treatment. The choice of this time framewas a
balance between accurately reflecting the clinical pathway and
appropriately using the available data, but a longer time perspec-
nd conservative scenario analysis. QALY, quality-adjustedrio, ative may alter the conclusions. This is a common challenge, and
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[15,16]. A probabilistic Markov cost-utility analysis has also dem-
onstrated escitalopram dominance over duloxetine over a 1-year
timehorizon [26]. Further longer-termprospective economic stud-
ies or modeling analyses, however, are needed to document how
the cost benefits achieved with escitalopram versus venlafaxine
are maintained over the longer term.
Another limitation was a scarcity of data sources, requiring
some assumptions about input parameters. For instance, AEs
weremodeled only over the first 8weeks, conservatively assuming
no difference in the probabilities of AEs between treatment arms
for the subsequent 4months.With the clinical evidence thatmost
AEs occur early in the course of treatment, however, this assump-
tion is unlikely to have an impact on the conclusions of the anal-
ysis. The model also assumed no additional resource use for AEs
beyond drugs to treat the AEs; however, this assumption is justi-
fied with generally mild-level severity of the AEs associated with
SSRIs, typically not associated with other health-care resource
use. Another assumption was a similar probability of relapse be-
tween the treatment arms, justified by the observations in clinical
studies of the two drugs [17-20].
Finally, the model accounted only for major treatment pat-
terns based on the HEADIS data, such as titration or treatment
discontinuation in case of nonresponse to the acute 8-week
treatment, not accounting for other options such as augmenta-
tion. This potential limitation is justified with the HEADIS data
source being specific to Sweden and hence reflects local treat-
ment patterns [14].
A variety of different modeling approaches can and have been
used in depression. Previous publications have also used a deci-
Table 5 – Results from one-way sensitivity analyses (costs
Outcome
Base-case value Sensitivity an
Remission probability (8 wk)
62.1% 55.
68.
Sick leave (number of days)
Remission
38.45 29.
47.
Switch
81.32 57.
104.
Stop
48.57 27.
69.
GP visits (number)
Remission 2.
Switch
4.39 3.
5.
Stop
4.8 3.
6.
Probability (8 wk) of nausea with escitalopram
12.7% 8.
17.
GP, general practitioner; QALY, quality-adjusted life-years.sion analytic model [15,16] and, in this case, the analysis based on ga decision-tree model was also related to the choice to keep a
simple framework, which was supported by real-life data requir-
ing fewer assumptions.
Several sensitivity analyses demonstrated that the model
results were robust to potential uncertainties and assumptions.
Furthermore, the economic benefits of escitalopram reported in
this analysis may be conservative because the model did not
incorporate other known advantages of escitalopram. For in-
stance, a significantly faster onset of remission with escitalo-
pram versus venlafaxine [4] might potentially be associated
ith additional savings in direct treatment costs and savings
elated to a faster reduction in sick leave. In addition, because of
ata scarcity, the model conservatively assumed no additional
isits to the physician associated with the treatment of AEs; this
ight result in underestimation of cost savings associated with
olerability benefits of escitalopram compared with venlafax-
ne.
In the current health-care environment, important chal-
enges are arising in clinical and health economics evaluations
nd further research is needed to build on the analyses pre-
ented in this article. In particular, treatments are becoming
ncreasingly tailored to selected patient groups rather than the
roader disease population, allowing health-care decision mak-
rs to reduce uncertainty, improve care, and enhance the effi-
iency of health-care resource utilization [27]. Therefore, CE ev-
dence increasingly needs to be focused on specific patient
opulations. This requires new clinical and observational stud-
es to provide robust underlying data regarding different patient
ubgroups with MDD, which can be used for future more tar-
2009).
Outcomes
(mean)
Incremental
sensitivity
analyses
Incremental
base-case
analysess values
Total costs 96.48 169.15
QALYs 0.0009 0.0087
Total costs 411.55 169.15
QALYs 0.0162 0.0087
Total 2206 1762
Total 1195 1762
Total 1006 1762
Total 2396 1762
Total 1125 1762
Total 2277 1762
Total 1712 1762
Total 1689 1762
Total 1714 1762
Total 1970 1762
Total 1733 1762
Total 1705 1762
QALYs 0.0091 0.0087
Total 1698 1762
QALYs 0.0082 0.0087in €
alyse
9%
1%
52
38
88
76
16
98
88
74
04
07
53
9%
2%eted economic evaluations.
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Escitalopram is more effective and cost saving compared with ge-
neric venlafaxine XR in the first-line treatment of MDD in Sweden.
These benefits are driven by the effectiveness and tolerability ad-
vantages of escitalopram, resulting in improved health-related
quality of life and probability of sustained remission and lower
health-care resource utilization and sick leave. The reduction in
indirect costs due to sick leave is the major driver of savings in
overall costs. These findings are robust and are maintained even
in a conservative analysis in which the cost of generic venlafaxine
XR is 5% of the branded version of the drug. The results of this
analysis are in line with other pharmacoeconomic analyses com-
paring escitalopram with venlafaxine.
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